Solanki Raghu, Rostamabadi Hadis, Patel Sunita, Jafari Seid Mahdi
School of Life Sciences, Central University of Gujarat, Sector-30, Gandhinagar 382030, India.
Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Int J Biol Macromol. 2021 Dec 15;193(Pt A):528-540. doi: 10.1016/j.ijbiomac.2021.10.040. Epub 2021 Oct 13.
Among the health-promotional protein-based vehicles, bovine serum albumin nanoparticles (BSA NPs) are particularly interesting. Meeting requirements e. g., non-toxicity, non-immunogenicity, biodegradability, biocompatibility, and high drug-binding capacity, has introduced BSA NPs as a promising candidate for efficient anti-cancer drug delivery and its application is now a rapidly-growing strategy to promote cancer therapy. Nevertheless, the leverage of such carriers requires an in-depth understanding of structural/physicochemical features of the BSA molecule and its derived nanovehicles, together with the utilized nano-formulation approaches, effective variables in delivery mechanism, specific shortfalls, and recent nanoencapsulation progresses. The current review highlights the novel advances in the application of BSA NPs to engineer drug vehicles for delivering anti-cancer agents. The factors influencing the efficiency of the therapeutics in such nano-delivery systems, alongside their advantaged and limitations are also discussed.
在基于蛋白质的健康促进载体中，牛血清白蛋白纳米颗粒（BSA NPs）尤其引人注目。满足诸如无毒、无免疫原性、生物可降解性、生物相容性和高药物结合能力等要求，使BSA NPs成为高效抗癌药物递送的有前途的候选者，其应用目前是促进癌症治疗的一种快速发展的策略。然而，利用此类载体需要深入了解BSA分子及其衍生纳米载体的结构/物理化学特征，以及所采用的纳米制剂方法、递送机制中的有效变量、特定不足和最近的纳米包封进展。本综述重点介绍了BSA NPs在设计用于递送抗癌剂的药物载体方面的新进展。还讨论了影响此类纳米递送系统中治疗效果的因素及其优势和局限性。
